Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Mar 15, 2021 (6 years ago)

Neomycin Sulf Tablets (Neomycin Sulfate)

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

CGMP Deviations: Intermittent exposure to temperature excursion during storage.

Cause type: Temperature excursion

The product was stored or shipped outside its labeled temperature range. Heat or freezing can degrade a drug without any visible change, so it may be weaker than labeled. All temperature excursion recalls.

What was recalled

NEOMYCIN SULF TABLETS, USP, 500mg, 100-count bottle, Rx Only, Distributed by: Teva Pharmaceuticals USA, Inc., North Wales, PA 19454, NDC: 0093-1177-01

Affected NDC 0093-1177-01

Compare with the code on your package — it is the most precise check available.

Drug: Neomycin

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Neomycin Sulfate
NDC 00093-1177
500 mg/1 Tablet
Oral
Teva Pharmaceuticals USA, Inc. Rx
Recalling firm
Cardinal Health Inc.
Origin
OH, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0574-2021 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Neomycin recalls

See all
Class II · Moderate risk

Med Pride

CGMP Deviations; deficiencies observed during FDA inspection

Ongoing cGMP deviation Dabur India Limited D-0642-2026
Class II · Moderate risk

Med Pride

CGMP Deviations; deficiencies observed during FDA inspection

Ongoing cGMP deviation Dabur India Limited D-0641-2026
Class II · Moderate risk

Rapidol

CGMP Deviations; deficiencies observed during FDA inspection

Ongoing cGMP deviation Dabur India Limited D-0633-2026
Class II · Moderate risk

Lil Drug Store

CGMP Deviations; deficiencies observed during FDA inspection

Ongoing cGMP deviation Dabur India Limited D-0632-2026
Class II · Moderate risk

Circle K

CGMP Deviations; deficiencies observed during FDA inspection

Ongoing cGMP deviation Dabur India Limited D-0631-2026

Other recalls by Cardinal Health Inc.

All 2021 recalls
Class II · Moderate risk

Enoxaparin Sodium Injection

Correct Labeled Product Mispack: Bags labeled for Enoxaparin Sodium Injection, 80 mg/0.8 mL, contained Enoxaparin Sodium Injection, 30 mg/0.3 mL

Ongoing Labeling / mix-up Cardinal Health Inc. NDC 55154-3543-5 D-0597-2025
Class II · Moderate risk

Recombinate

CGMP Deviations - Product was exposed to temperatures outside the product's labeled storage requirements.

Ongoing Temperature excursion Cardinal Health Inc. D-0573-2025
Class II · Moderate risk

Xolair (omalizumab injection)

CGMP Deviations - Product was exposed to temperatures outside the product's labeled storage requirements.

Ongoing Temperature excursion Cardinal Health Inc. NDC 50242-214-55 D-0572-2025